Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A Leal, Jonathan W Riess, Erin Jensen, Bin Zhao, M Catherine Pietanza, Julie R Brahmer, Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A Leal, Jonathan W Riess, Erin Jensen, Bin Zhao, M Catherine Pietanza, Julie R Brahmer
Abstract
Purpose: We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no sensitizing EGFR or ALK alterations. Previous analyses showed pembrolizumab significantly improved progression-free survival and overall survival (OS).
Methods: Eligible patients were randomly assigned (1:1) to pembrolizumab (200 mg once every 3 weeks for up to 35 cycles) or platinum-based chemotherapy. Patients in the chemotherapy group with progressive disease could cross over to pembrolizumab. The primary end point was progression-free survival; OS was a secondary end point.
Results: Three hundred five patients were randomly assigned: 154 to pembrolizumab and 151 to chemotherapy. Median (range) time from randomization to data cutoff (June 1, 2020) was 59.9 (55.1-68.4) months. Among patients initially assigned to chemotherapy, 99 received subsequent anti-PD-1 or PD-L1 therapy, representing a 66.0% effective crossover rate. Median OS was 26.3 months (95% CI, 18.3 to 40.4) for pembrolizumab and 13.4 months (9.4-18.3) for chemotherapy (hazard ratio, 0.62; 95% CI, 0.48 to 0.81). Kaplan-Meier estimates of the 5-year OS rate were 31.9% for the pembrolizumab group and 16.3% for the chemotherapy group. Thirty-nine patients received 35 cycles (ie, approximately 2 years) of pembrolizumab, 82.1% of whom were still alive at data cutoff (approximately 5 years). Toxicity did not increase with longer treatment exposure.
Conclusion: Pembrolizumab provides a durable, clinically meaningful long-term OS benefit versus chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.
Conflict of interest statement
Martin ReckConsulting or Advisory Role: Lilly, MSD Oncology, Merck Serono, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Roche/Genentech, Abbvie, Amgen, Mirati Therapeutics, Samsung BioepisSpeakers' Bureau: Roche/Genentech, Lilly, MSD Oncology, Merck Serono, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Pfizer, Novartis, Amgen, Mirati Therapeutics Delvys Rodríguez-AbreuConsulting or Advisory Role: Roche, Bristol Myers Squibb, MSD, AstraZeneca Spain, NovartisSpeakers' Bureau: Roche, Bristol Myers Squibb, MSDTravel, Accommodations, Expenses: Roche, Bristol Myers Squibb, MSD Andrew G. RobinsonHonoraria: MerckConsulting or Advisory Role: AstraZeneca, Merck, AmgenResearch Funding: AstraZeneca, Merck, Bristol Myers Squibb, Roche Canada Rina HuiHonoraria: Merck Sharp & Dohme, Novartis, Roche, AstraZeneca, Bristol Myers Squibb, Lilly, Pfizer, SeagenConsulting or Advisory Role: Merck Sharp & Dohme, AstraZeneca, Roche, Bristol Myers Squibb, Novartis, Lilly, Pfizer, SeagenResearch Funding: AstraZeneca, Lilly, Novartis, MSD, Roche, Seagen, OncoSecTravel, Accommodations, Expenses: Novartis Tibor CsősziConsulting or Advisory Role: NovartisSpeakers' Bureau: Ipsen, Janssen-CilagTravel, Accommodations, Expenses: Sanofi, Pfizer Andrea FülöpResearch Funding: MSD, AstraZeneca, Janssen Nir PeledHonoraria: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, Roche, TakedaConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer, RocheResearch Funding: MSD Oncology, Roche/Genentech, AstraZeneca, Takeda, Merck Serono, NovartisTravel, Accommodations, Expenses: Roche/Genentech, MSD Oncology, AstraZeneca, Pfizer Sinead CuffeTravel, Accommodations, Expenses: MSD Oncology, Roche, Pfizer, Bristol Myers Squibb Mary O'BrienHonoraria: Merck, Merck Serono, Abbvie, Bristol Myers SquibbConsulting or Advisory Role: MerckTravel, Accommodations, Expenses: Bristol Myers Squibb Suman RaoHonoraria: Merck, AstraZenecaConsulting or Advisory Role: Galvanize TherapeuticsSpeakers' Bureau: AstraZenecaTravel, Accommodations, Expenses: Merck Katsuyuki HottaHonoraria: AZD, MSD Oncology, Pfizer, Lilly, Taiho Pharmaceutical, Chugai Pharma, TakedaResearch Funding: MSD, Chugai Pharma, Lilly Japan, Bristol Myers Squibb, AZD Ticiana A. LealConsulting or Advisory Role: BeyondSpring Pharmaceuticals, Bristol Myers Squibb, Merck, Takeda, Genentech, InvisionFirst Lung, Novocure, Jazz Pharmaceuticals, AstraZeneca, Bayer, EMD Serono, Boehringer Ingelheim, Blueprint Medicines, Daiichi Sankyo/Lilly, Debiopharm Group, Genentech, LillyTravel, Accommodations, Expenses: Takeda, Abbvie, Bristol Myers Squibb, Genentech, Mirati Therapeutics, AstraZeneca, MerckUncompensated Relationships: Mirati Therapeutics Jonathan W. RiessConsulting or Advisory Role: Medtronic, Boehringer Ingelheim, Novartis, Blueprint Medicines, Genentech, EcoR1 Capital, Teladoc, Daiichi Sankyo, EMD SeronoResearch Funding: Merck, AstraZeneca/MedImmune, Spectrum Pharmaceuticals, Boehringer Ingelheim, Novartis, Revolution Medicines, GlaxoSmithKline Erin JensenEmployment: MerckStock and Other Ownership Interests: Merck Bin ZhaoEmployment: Merck Sharp & DohmeStock and Other Ownership Interests: Merck Sharp & Dohme M. Catherine PietanzaEmployment: MerckStock and Other Ownership Interests: Merck Sharp & Dohme Julie R. BrahmerHonoraria: Roche/GenentechConsulting or Advisory Role: Bristol Myers Squibb, Lilly, Merck, Amgen, Genentech, GlaxoSmithKline, AstraZeneca, Regeneron, SanofiResearch Funding: Bristol Myers Squibb, AstraZeneca, Spectrum Pharmaceuticals, Revolution, RAPT Therapeutics, Genentech/RocheTravel, Accommodations, Expenses: Bristol Myers Squibb, Roche/GenentechOther Relationship: Bristol Myers Squibb, Merck, Janssen OncologyNo other potential conflicts of interest were reported.
Figures
References
- Howlader N Noone AM Krapcho M, et al. : SEER Cancer Statistics Review, 1975-2014. Bethesda, MD, National Cancer Institute, 2017
- Butler CA Darragh KM Currie GP, et al. : Variation in lung cancer survival rates between countries: Do differences in data reporting contribute? Respir Med 100:1642-1646, 2006
- National Comprehensive Cancer Network (NCCN) : NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small Cell Lung Cancer. Version 2.2020.
- Reck M Rodriguez-Abreu D Robinson AG, et al. : Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537-546, 2019
- Mok TSK Wu YL Kudaba I, et al. : Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 393:1819-1830, 2019
- Paz-Ares L Luft A Vicente D, et al. : Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040-2051, 2018
- Gandhi L Rodriguez-Abreu D Gadgeel S, et al. : Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078-2092, 2018
- Paz-Ares L Vicente D Tafreshi A, et al. : A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15:1657-1669, 2020
- Gadgeel S Rodríguez-Abreu D Speranza G, et al. : Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol 38:1505-1517, 2020
- Reck M Rodriguez-Abreu D Robinson AG, et al. : Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
- Garon EB Hellmann MD Rizvi NA, et al. : Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study. J Clin Oncol 37:2518-2527, 2019
- Borghaei H Paz-Ares L Horn L, et al. : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
- Brahmer J Reckamp KL Baas P, et al. : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123-135, 2015
- Rittmeyer A Barlesi F Waterkamp D, et al. : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017
- Fehrenbacher L Spira A Ballinger M, et al. : Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837-1846, 2016
- Herbst RS Garon EB Kim DW, et al. : Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 38:1580-1590, 2020
- Brahmer JR Rodriguez-Abreu D Robinson AG, et al. : Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. J Thorac Oncol 12:S8-S9, 2017
- Langer CJ Gadgeel SM Borghaei H, et al. : Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497-1508, 2016
- Borghaei H Langer CJ Gadgeel S, et al. : 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung cancer. J Thorac Oncol 14:124-129, 2019
- Reck M Ciuleanu T-E Dols MC, et al. : Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol 38, 2020. (suppl; abstr 9501)
- Hellmann MD Paz-Ares L Bernabe Caro R, et al. : Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020-2031, 2019
- Socinski MA Jotte RM Cappuzzo F, et al. : Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288-2301, 2018
- West H McCleod M Hussein M, et al. : Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924-937, 2019
- Sezer A Kilickap S Gümüş M, et al. : LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Ann Oncol 31:S1182-S1183, 2020
- Howlader N Forjaz G Mooradian MJ, et al. : The effect of advances in lung-cancer treatment on population mortality. N Engl J Med 383:640-649, 2020
Source: PubMed